Research team on microbiome in pediatric patients affected by oncological and hematological diseases @UniversityofBologna. Share ideas, welcome collaborations.
🆕 in @BloodJournal: Increased gut microbiome diversity may lead to better outcomes among children receiving stem cell transplants. Read more: loom.ly/XJqZlOs
Very proud to share our new paper in Blood Journal! First time in children Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as predictor of mortality in children ashpublications.org/blood/ar…
Very proud to share our new paper! Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML: a multicenter retrospective analysis ashpublications.org/bloodadv…
We are very happy to share our new paper on Venetoclax-based therapies in pediatric advanced MDS and relapsed/refractory AML! ashpublications.org/bloodadv…
La leucemia mieloide acuta è un tumore raro del sangue ancora da studiare. Nasce la Rete italiana “PALM” di istituti specializzati in campo oncoematologico coordinata dall’ @bambinogesu , finanziata da Fondazione Umberto Veronesi➡bit.ly/3QZ4fLv
There is an unmet need for better methods of diagnosing GvHD, identifying at-risk patients & determining which patients are at highest risk of severity & poor outcomes. Read about updated GVHD biomarkers on Nucleus: ow.ly/GrEX50Mvl10
Very happy to share our paper on effect of levofloxacin prophylaxis and parenteral nutrition on intestinal microbial in pediatric patients undergoing HSCT… we test a new network approach! #microbiotanature.com/articles/s42003-0…
Salutiamo Gianluca Vialli con le parole che lui ha dedicato ai nostri ricercatori e alle nostre ricercatrici solo pochi mesi fa. Ci stringiamo alla sua famiglia in questo momento.
Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome mdpi.com/1989612#mdpiijms via @IJMS_MDPI
Interesting paper on mycobiome in #fmt Profiling the fungal microbiome after FMT for graft-versus-host disease: insights from a phase 1 interventional study - ScienceDirect sciencedirect.com/science/ar…
High dose cyclophosphamide (HiCY) has changed landscape of alloBMT by expanding donor pool and allowing for relative safe and effective use of haplo donors. Esp useful in non-malig dz such as SAA and SCD where cure rates now approach 90%. Why does HiCY work?